Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Long Cast Advisers Avram Fisher | “Despite market anxieties regarding artificial intelligence displacing the information services industry, Research Solutions is well-positioned to adopt and build around AI tools. With attractive cash flow generation and deferred revenue indicating an operational improvement slope, the company also stands to benefit from academic budget tightening and potential acquisition interest.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Long Cast Advisers Avram Fisher | “RSSS ($2.57 avg price). The company sells a subscription product on a per seat basis to an industry that faces contraction as a result of the US federal government withdrawing funds from research and science. My divergent view is that I think it can gain share in a shrinking market, while the stock market prices this as if it can't. BSD Analysis: Research Solutions is a niche content and workflow platform monetizing academic and corporate research access. Its value lies in simplifying procurement and compliance, not content ownership. Growth looks unexciting, but churn is low because workflows get embedded. Investors overlook the stickiness because the business is small and unflashy. Operating leverage improves meaningfully at scale. Expansion comes from deeper customer penetration, not splashy new markets. This is research plumbing quietly compounding.” | BULL | Q4 2025 Jan 1, 2026 | View Pitch |
Long Cast Advisers Avram Fisher | “RSSS also reported F1Q26 results, it‚Äôs seasonally slowest. It is growing and generating cash and helmed by an experienced C-suite and an impassioned product developer, the founder of Scite, which the company purchased in 2023. The company is broadly engaged in rights access to scientific literature; the legacy of the business is licensing libraries of scientific literature, bulk breaking that access and wrapping services around it. Given this description, it‚Äôs easy to extrapolate risks from disintermediation (publishers selling direct), from AI platforms that pay for rights and from open access scientific research. These at-hand reasons explain why this investment opportunity exists. There‚Äôs a different perspective. Unlike the world of politics and entertainment where we tolerate and accept fiction, the world of science relies on facts and therefore requires a higher level of curation than what‚Äôs available in other spheres. This is especially true in a world of open access where research is free and ‚Äúpaper mills‚Äù churn out fake articles. The need for a solution isn‚Äôt going away. The RSSS solution, Scite, differentiates itself by offering contextualized citation searches that includes whether underlying papers are supporting, contrasting or retracted, and they are building their brand around this capability. Is it a durable advantage? It‚Äôs impossible to say. This is still a small company in an industry seeing rapid development. I think our advantage is the quality of our experienced and entrepreneurial management team building a culture of growth and cash flow, and product development that tries to stay ahead of the customer. BSD Analysis: The core investment thesis for Research Solutions centers on its aggressive and successful transition from a legacy document delivery service to a high-growth, vertical SaaS and AI platform for the scientific research market. The company is actively compounding value by driving its high-margin Platforms revenue (up 21% YoY) to become a larger portion of the business mix, dramatically improving the blended gross margin to over 50%. Crucially, B2B Annual Recurring Revenue (ARR) grew over 300% in the recent quarter, reflecting strong new customer generation and expansion within existing accounts. Management is focused on achieving the "Rule of 40" benchmark, having already driven a strong 16% Adjusted EBITDA growth and achieving a record $7.0 million in operating cash flow. This momentum is underpinned by its unique, publisher-independent platform that leverages AI-powered tools to accelerate discovery and manage research rights for major life science and corporate clients. Trading at a reasonable valuation for a SaaS player with strong unit economics, the stock is positioned for significant long-term multiple expansion as the high-margin platform fully eclipses the slower-growth transaction business.” | BULL | Q3 2025 Nov 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
